Differential in vivo activities of bovine growth hormone analogues.
In rodents, bovine (b) growth hormone (GH) binds only to GH receptors, while human (h) GH binds to both GH and PRL receptors. The phenotypic consequences of expression of bGH and hGH in transgenic mice are different and, in some cases, opposite. In the present study, site-directed in vitro mutagenesis of the bGH gene was used systematically to eliminate its differences from hGH at one, two, three or four suspected of conferring lactogenic activity: D11, H18, S57 and T60, respectively (corresponding to sites 12, 19, 57 and 60 of the bGH molecule). The resulting bGH analogues were expressed in cell lines and in transgenic mice. All of the seven bGH analogues produced retained their ability to bind to GH receptors and exhibited somatogenic activity in vitro and in vivo. However, none of them were able to bind to PRL receptors or to elicit detectable lactogenic response in vitro. Transgenic animals expressing any of the generated analogues were characterized by gigantism and splanchnomegaly. The effects of expression of each of the double, triple or quadruple mutants on the seminal vesicle weight resembled the effects of wild-type hGH and differed from the effects of expression of wild-type bGH. There were differences between the effects of the expression of different bGH analogues on plasma PRL levels and on the PRL response to pharmacological blockade of catecholamine synthesis. Plasma LH levels in ovariectomized females were suppressed by several of the analogues tested, an effect not seen in animals expressing wild-type bGH or hGH. Dopamine turnover in the median eminence of male mice was also altered in animals expressing different bGH analogues but not in those expressing wild-type bGH or hGH. In ovariectomized females, the effects of different bGH analogs on the turnover of dopamine and norepinephrine in the median eminence included changes resembling those detected in animals expressing hGH, as well as alterations differing from the effects of both bGH and hGH. The results indicate that biological actions of these bGH analogues cannot be characterized simply in terms of enhanced or reduced somatogenic or lactogenic activity and raise a possibility that different sites, domains or features of tri-dimensional structure of GH are involved in its actions on different cellular targets.
Kopchick
J
J
Edison Biotechnology Institute, Ohio University College of Osteopathic Medicine, Ohio University, Athens 45701, USA.
Chen
X Z
XZ
Li
Y
Y
Steger
R W
RW
Yun
J S
JS
Wagner
T E
TE
Bartke
A
A
D000818:Animals; D001665:Binding Sites; D001667:Binding, Competitive; D002417:Cattle; D002478:Cells, Cultured; D004298:Dopamine / Q000378:metabolism; D005260:Female; D015870:Gene Expression; D013006:Growth Hormone / Q000031:analogs & derivatives* / Q000235:genetics* / Q000378:metabolism; D006801:Humans; D007774:Lactation / Q000378:metabolism; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D016297:Mutagenesis, Site-Directed; D009638:Norepinephrine / Q000378:metabolism; D010641:Phenotype; D010957:Plasmids; D011388:Prolactin / Q000097:blood / Q000378:metabolism*; D011986:Receptors, Somatotropin / Q000378:metabolism
D011986:Receptors, Somatotropin; D011388:Prolactin; D013006:Growth Hormone; D004298:Dopamine; D009638:Norepinephrine